Danielle Graham PhD

Dr. Danielle Graham received her PhD from Baylor University. After completing her doctoral training, she pursued a postdoctoral fellowship at the University of Texas Southwestern Medical Center in Dallas, TX, where she characterized the role of BNDF and CREB in the mesolimbic dopamine system in neuropsychiatric illnesses. Dr. Graham moved to Boston, MA, in 2007 to join the Neurobiology department at Merck Research Labs. As a research biologist at Merck, she contributed to the early-stage drug discovery pipeline by developing novel pharmacodynamic and efficacy models for CNS Diseases. In 2009, she moved to EMD Serono and joined the Translational Neuropharmacology group.

At EMD Serono, she was responsible for leading a team of scientists in the characterization of novel therapeutics and biomarker endpoints for AD, PD, and MS. In 2014, she moved to Biogen and joined the Translational Sciences group at Biogen, where she has had roles with increasing responsibility over the years. At present, Dr. Graham is Vice President, Head of Fluid Biomarkers and Bioanalytics at Biogen. Dr Graham and her team played a critical role in the recent accelerated approval of Tofersen, a novel therapy in SOD1 ASO. Tofersen was granted accelerated approval based on the data generated on neurofilament, indicating NfL is a surrogate endpoint reasonably likely to predict clinical benefit.